{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:50:03Z","timestamp":1793400603127,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T00:00:00Z","timestamp":1610496000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T00:00:00Z","timestamp":1610496000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG066707"],"award-info":[{"award-number":["R01AG066707"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R56AG063870"],"award-info":[{"award-number":["R56AG063870"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["P30 AGO62428-01"],"award-info":[{"award-number":["P30 AGO62428-01"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["P20GM109025"],"award-info":[{"award-number":["P20GM109025"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000967","name":"American Health Assistance Foundation","doi-asserted-by":"publisher","award":["19PABH134580006"],"award-info":[{"award-number":["19PABH134580006"]}],"id":[{"id":"10.13039\/100000967","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["P20GM109025"],"award-info":[{"award-number":["P20GM109025"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["U01NS093334"],"award-info":[{"award-number":["U01NS093334"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R01AG053798"],"award-info":[{"award-number":["R01AG053798"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["3R01AG066707-01S1"],"award-info":[{"award-number":["3R01AG066707-01S1"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Recent DNA\/RNA sequencing and other multi-omics technologies have advanced the understanding of the biology and pathophysiology of AD, yet there is still a lack of disease-modifying treatments for AD. A new approach to integration of the genome, transcriptome, proteome, and human interactome in the drug discovery and development process is essential for this endeavor.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this study, we developed AlzGPS (\n                      <jats:italic>G<\/jats:italic>\n                      enome-wide\n                      <jats:italic>P<\/jats:italic>\n                      ositioning\n                      <jats:italic>S<\/jats:italic>\n                      ystems platform for\n                      <jats:italic>Alz<\/jats:italic>\n                      heimer\u2019s Drug Discovery,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/alzgps.lerner.ccf.org\">https:\/\/alzgps.lerner.ccf.org<\/jats:ext-link>\n                      ), a comprehensive systems biology tool to enable searching, visualizing, and analyzing multi-omics, various types of heterogeneous biological networks, and clinical databases for target identification and development of effective prevention and treatment for AD.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Via AlzGPS: (1) we curated more than 100 AD multi-omics data sets capturing DNA, RNA, protein, and small molecule profiles underlying AD pathogenesis (e.g., early vs. late stage and tau or amyloid endophenotype); (2) we constructed endophenotype disease modules by incorporating multi-omics findings and human protein-protein interactome networks; (3) we provided possible treatment information from ~\u20093000 FDA approved\/investigational drugs for AD using state-of-the-art network proximity analyses; (4) we curated nearly 300 literature references for high-confidence drug candidates; (5) we included information from over 1000\u2009AD clinical trials noting drug\u2019s mechanisms-of-action and primary drug targets, and linking them to our integrated multi-omics view for targets and network analysis results for the drugs; (6) we implemented a highly interactive web interface for database browsing and network visualization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Network visualization enabled by AlzGPS includes brain-specific neighborhood networks for genes-of-interest, endophenotype disease module networks for omics-of-interest, and mechanism-of-action networks for drugs targeting disease modules. By virtue of combining systems pharmacology and network-based integrative analysis of multi-omics data, AlzGPS offers actionable systems biology tools for accelerating therapeutic development in AD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-020-00760-w","type":"journal-article","created":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T07:04:09Z","timestamp":1610521449000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":84,"title":["AlzGPS: a genome-wide positioning systems platform to catalyze multi-omics for Alzheimer\u2019s drug discovery"],"prefix":"10.1186","volume":"13","author":[{"given":"Yadi","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiansong","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn M.","family":"Bekris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Heon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew A.","family":"Pieper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James B.","family":"Leverenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1736-2847","authenticated-orcid":false,"given":"Feixiong","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,13]]},"reference":[{"key":"760_CR1","doi-asserted-by":"crossref","unstructured":"2020 Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 2020;16(3):391\u2013460.","DOI":"10.1002\/alz.12068"},{"issue":"2","key":"760_CR2","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","volume":"179","author":"JM Long","year":"2019","unstructured":"Long JM, Holtzman DM. Alzheimer disease: an update on pathobiology and treatment strategies. Cell. 2019;179(2):312\u201339.","journal-title":"Cell."},{"key":"760_CR3","doi-asserted-by":"publisher","first-page":"15056","DOI":"10.1038\/nrdp.2015.56","volume":"1","author":"CL Masters","year":"2015","unstructured":"Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA, Cummings JL. Alzheimer\u2019s disease. Nat Rev Dis Primers. 2015;1:15056.","journal-title":"Nat Rev Dis Primers"},{"issue":"12","key":"760_CR4","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/nrd.2017.169","volume":"16","author":"AT Kodamullil","year":"2017","unstructured":"Kodamullil AT, Zekri F, Sood M, Hengerer B, Canard L, McHale D, et al. Trial watch: tracing investment in drug development for Alzheimer disease. Nat Rev Drug Discov. 2017;16(12):819.","journal-title":"Nat Rev Drug Discov"},{"issue":"7731","key":"760_CR5","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/d41586-018-07352-7","volume":"563","author":"E Alteri","year":"2018","unstructured":"Alteri E, Guizzaro L. Be open about drug failures to speed up research. Nature. 2018;563(7731):317\u20139.","journal-title":"Nature."},{"issue":"6","key":"760_CR6","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1002\/med.21709","volume":"40","author":"J Fang","year":"2020","unstructured":"Fang J, Pieper AA, Nussinov R, Lee G, Bekris L, Leverenz JB, et al. Harnessing endophenotypes and network medicine for Alzheimer\u2019s drug repurposing. Med Res Rev. 2020;40(6):2386\u2013426.","journal-title":"Med Res Rev"},{"issue":"1","key":"760_CR7","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13195-019-0529-5","volume":"11","author":"J Cummings","year":"2019","unstructured":"Cummings J, Feldman HH, Scheltens P. The \u201crights\u201d of precision drug development for Alzheimer\u2019s disease. Alzheimers Res Ther. 2019;11(1):76.","journal-title":"Alzheimers Res Ther"},{"issue":"7","key":"760_CR8","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.cell.2017.05.018","volume":"169","author":"H Keren-Shaul","year":"2017","unstructured":"Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, et al. A unique microglia type associated with restricting development of Alzheimer\u2019s disease. Cell. 2017;169(7):1276\u201390 e17.","journal-title":"Cell."},{"issue":"12","key":"760_CR9","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1038\/ng.2802","volume":"45","author":"JC Lambert","year":"2013","unstructured":"Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer\u2019s disease. Nat Genet. 2013;45(12):1452\u20138.","journal-title":"Nat Genet"},{"issue":"6","key":"760_CR10","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.neuron.2019.12.015","volume":"105","author":"B Bai","year":"2020","unstructured":"Bai B, Wang X, Li Y, Chen PC, Yu K, Dey KK, et al. Deep multilayer brain proteomics identifies molecular networks in Alzheimer\u2019s disease progression. Neuron. 2020;105(6):975\u201391 e7.","journal-title":"Neuron."},{"issue":"1","key":"760_CR11","doi-asserted-by":"publisher","first-page":"3476","DOI":"10.1038\/s41467-019-10744-6","volume":"10","author":"F Cheng","year":"2019","unstructured":"Cheng F, Lu W, Liu C, Fang J, Hou Y, Handy DE, et al. A genome-wide positioning systems network algorithm for in silico drug repurposing. Nat Commun. 2019;10(1):3476.","journal-title":"Nat Commun"},{"issue":"1","key":"760_CR12","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1038\/s41467-018-05116-5","volume":"9","author":"F Cheng","year":"2018","unstructured":"Cheng F, Desai RJ, Handy DE, Wang R, Schneeweiss S, Barabasi AL, et al. Network-based approach to prediction and population-based validation of in silico drug repurposing. Nat Commun. 2018;9(1):2691.","journal-title":"Nat Commun"},{"issue":"5","key":"760_CR13","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/s41593-019-0382-7","volume":"22","author":"Q Wang","year":"2019","unstructured":"Wang Q, Chen R, Cheng F, Wei Q, Ji Y, Yang H, et al. A Bayesian framework that integrates multi-omics data and gene networks predicts risk genes from schizophrenia GWAS data. Nat Neurosci. 2019;22(5):691\u20139.","journal-title":"Nat Neurosci"},{"key":"760_CR14","doi-asserted-by":"publisher","unstructured":"Fang J, Zhang P, Wang Q, Zhou Y, Chiang WC, Cheng R, et al. Network-based translation of GWAS findings to pathobiology and drug repurposing for Alzheimer\u2019s disease. medRxiv. 2020:2020.01.15.20017160. https:\/\/doi.org\/10.1101\/2020.01.15.20017160.","DOI":"10.1101\/2020.01.15.20017160"},{"key":"760_CR15","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41421-020-0153-3","volume":"6","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Hou Y, Shen J, Huang Y, Martin W, Cheng F. Network-based drug repurposing for novel coronavirus 2019-nCoV\/SARS-CoV-2. Cell Discov. 2020;6:14.","journal-title":"Cell Discov"},{"issue":"12","key":"760_CR16","doi-asserted-by":"publisher","first-page":"e667","DOI":"10.1016\/S2589-7500(20)30192-8","volume":"2","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Wang F, Tang J, Nussinov R, Cheng F. Artificial intelligence in COVID-19 drug repurposing. Lancet Digit Health. 2020;2(12):e667\u2013e76.","journal-title":"Lancet Digit Health"},{"issue":"1","key":"760_CR17","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1093\/nar\/30.1.207","volume":"30","author":"R Edgar","year":"2002","unstructured":"Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002;30(1):207\u201310.","journal-title":"Nucleic Acids Res"},{"issue":"Database issue","key":"760_CR18","first-page":"D991","volume":"41","author":"T Barrett","year":"2013","unstructured":"Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, et al. NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2013;41(Database issue):D991\u20135.","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"760_CR19","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"760_CR20","doi-asserted-by":"publisher","first-page":"D786","DOI":"10.1093\/nar\/gky930","volume":"47","author":"B Braschi","year":"2019","unstructured":"Braschi B, Denny P, Gray K, Jones T, Seal R, Tweedie S, et al. Genenames.org: the HGNC and VGNC resources in 2019. Nucleic Acids Res. 2019;47(D1):D786\u2013D92.","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"760_CR21","doi-asserted-by":"publisher","first-page":"D1005","DOI":"10.1093\/nar\/gky1120","volume":"47","author":"A Buniello","year":"2019","unstructured":"Buniello A, MacArthur JAL, Cerezo M, Harris LW, Hayhurst J, Malangone C, et al. The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. Nucleic Acids Res. 2019;47(D1):D1005\u2013D12.","journal-title":"Nucleic Acids Res"},{"issue":"Database issue","key":"760_CR22","doi-asserted-by":"publisher","first-page":"D1091","DOI":"10.1093\/nar\/gkt1068","volume":"42","author":"V Law","year":"2014","unstructured":"Law V, Knox C, Djoumbou Y, Jewison T, Guo AC, Liu Y, et al. DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res. 2014;42(Database issue):D1091\u20137.","journal-title":"Nucleic Acids Res"},{"issue":"11","key":"760_CR23","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1021\/ci300367a","volume":"52","author":"F Cheng","year":"2012","unstructured":"Cheng F, Li W, Zhou Y, Shen J, Wu Z, Liu G, et al. admetSAR: a comprehensive source and free tool for assessment of chemical ADMET properties. J Chem Inf Model. 2012;52(11):3099\u2013105.","journal-title":"J Chem Inf Model"},{"issue":"11","key":"760_CR24","doi-asserted-by":"publisher","first-page":"4959","DOI":"10.1021\/acs.jcim.9b00969","volume":"59","author":"F Cheng","year":"2019","unstructured":"Cheng F, Li W, Zhou Y, Shen J, Wu Z, Liu G, et al. Correction to \u201cadmetSAR: a comprehensive source and free tool for assessment of chemical ADMET properties\u201d. J Chem Inf Model. 2019;59(11):4959.","journal-title":"J Chem Inf Model"},{"issue":"D1","key":"760_CR25","doi-asserted-by":"publisher","first-page":"D1069","DOI":"10.1093\/nar\/gkv1230","volume":"44","author":"H Yang","year":"2016","unstructured":"Yang H, Qin C, Li YH, Tao L, Zhou J, Yu CY, et al. Therapeutic target database update 2016: enriched resource for bench to clinical drug target and targeted pathway information. Nucleic Acids Res. 2016;44(D1):D1069\u201374.","journal-title":"Nucleic Acids Res"},{"issue":"Database issue","key":"760_CR26","doi-asserted-by":"publisher","first-page":"D1100","DOI":"10.1093\/nar\/gkr777","volume":"40","author":"A Gaulton","year":"2012","unstructured":"Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, et al. ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res. 2012;40(Database issue):D1100\u20137.","journal-title":"Nucleic Acids Res"},{"issue":"Database issue","key":"760_CR27","doi-asserted-by":"publisher","first-page":"D198","DOI":"10.1093\/nar\/gkl999","volume":"35","author":"T Liu","year":"2007","unstructured":"Liu T, Lin Y, Wen X, Jorissen RN, Gilson MK. BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res. 2007;35(Database issue):D198\u2013201.","journal-title":"Nucleic Acids Res"},{"issue":"Database issue","key":"760_CR28","doi-asserted-by":"publisher","first-page":"D1098","DOI":"10.1093\/nar\/gkt1143","volume":"42","author":"AJ Pawson","year":"2014","unstructured":"Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al. The IUPHAR\/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucleic Acids Res. 2014;42(Database issue):D1098\u2013106.","journal-title":"Nucleic Acids Res"},{"key":"760_CR29","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.trci.2018.03.009","volume":"4","author":"J Cummings","year":"2018","unstructured":"Cummings J, Lee G, Ritter A, Zhong K. Alzheimer\u2019s disease drug development pipeline: 2018. Alzheimers Dement (N Y). 2018;4:195\u2013214.","journal-title":"Alzheimers Dement (N Y)."},{"key":"760_CR30","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.trci.2019.05.008","volume":"5","author":"J Cummings","year":"2019","unstructured":"Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K. Alzheimer\u2019s disease drug development pipeline: 2019. Alzheimers Dement (N Y). 2019;5:272\u201393.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"1","key":"760_CR31","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/s41467-019-09186-x","volume":"10","author":"F Cheng","year":"2019","unstructured":"Cheng F, Kovacs IA, Barabasi AL. Network-based prediction of drug combinations. Nat Commun. 2019;10(1):1197.","journal-title":"Nat Commun"},{"issue":"5","key":"760_CR32","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.ajhg.2019.03.009","volume":"104","author":"IN Smith","year":"2019","unstructured":"Smith IN, Thacker S, Seyfi M, Cheng F, Eng C. Conformational dynamics and allosteric regulation landscapes of germline PTEN mutations associated with autism compared to those associated with cancer. Am J Hum Genet. 2019;104(5):861\u201378.","journal-title":"Am J Hum Genet"},{"key":"760_CR33","volume-title":"Exploring network structure, dynamics, and function using NetworkX. Proceedings of the 7th Python in Science Conference (SciPy2008)","author":"A Hagberg","year":"2008","unstructured":"Hagberg A, Schult D, Swart P. Exploring network structure, dynamics, and function using NetworkX. Proceedings of the 7th Python in Science Conference (SciPy2008); 2008."},{"issue":"2","key":"760_CR34","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/bioinformatics\/btv557","volume":"32","author":"M Franz","year":"2016","unstructured":"Franz M, Lopes CT, Huck G, Dong Y, Sumer O, Bader GD. Cytoscape.js: a graph theory library for visualisation and analysis. Bioinformatics. 2016;32(2):309\u201311.","journal-title":"Bioinformatics."},{"issue":"11","key":"760_CR35","doi-asserted-by":"publisher","first-page":"4044","DOI":"10.1073\/pnas.83.11.4044","volume":"83","author":"KS Kosik","year":"1986","unstructured":"Kosik KS, Joachim CL, Selkoe DJ. Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc Natl Acad Sci U S A. 1986;83(11):4044\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"760_CR36","doi-asserted-by":"publisher","first-page":"4051","DOI":"10.1073\/pnas.85.11.4051","volume":"85","author":"M Goedert","year":"1988","unstructured":"Goedert M, Wischik CM, Crowther RA, Walker JE, Klug A. Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. Proc Natl Acad Sci U S A. 1988;85(11):4051\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"760_CR37","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/nan.12208","volume":"41","author":"GG Kovacs","year":"2015","unstructured":"Kovacs GG. Invited review: neuropathology of tauopathies: principles and practice. Neuropathol Appl Neurobiol. 2015;41(1):3\u201323.","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"43","key":"760_CR38","doi-asserted-by":"publisher","first-page":"69225","DOI":"10.18632\/oncotarget.12648","volume":"7","author":"H Jing","year":"2016","unstructured":"Jing H, Zhu JX, Wang HF, Zhang W, Zheng ZJ, Kong LL, et al. INPP5D rs35349669 polymorphism with late-onset Alzheimer\u2019s disease: a replication study and meta-analysis. Oncotarget. 2016;7(43):69225\u201330.","journal-title":"Oncotarget."},{"key":"760_CR39","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.neurobiolaging.2019.06.003","volume":"81","author":"X Yao","year":"2019","unstructured":"Yao X, Risacher SL, Nho K, Saykin AJ, Wang Z, Shen L, et al. Targeted genetic analysis of cerebral blood flow imaging phenotypes implicates the INPP5D gene. Neurobiol Aging. 2019;81:213\u201321.","journal-title":"Neurobiol Aging"},{"key":"760_CR40","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1146\/annurev.genom.1.1.507","volume":"1","author":"RW Mahley","year":"2000","unstructured":"Mahley RW, Rall SC Jr. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet. 2000;1:507\u201337.","journal-title":"Annu Rev Genomics Hum Genet"},{"issue":"2","key":"760_CR41","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nrneurol.2012.263","volume":"9","author":"CC Liu","year":"2013","unstructured":"Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013;9(2):106\u201318.","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"760_CR42","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/85064","volume":"4","author":"H Cai","year":"2001","unstructured":"Cai H, Wang Y, McCarthy D, Wen H, Borchelt DR, Price DL, et al. BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat Neurosci. 2001;4(3):233\u20134.","journal-title":"Nat Neurosci"},{"key":"760_CR43","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.neuint.2018.12.015","volume":"127","author":"P Venkat","year":"2019","unstructured":"Venkat P, Chopp M, Zacharek A, Cui C, Landschoot-Ward J, Qian Y, et al. Sildenafil treatment of vascular dementia in aged rats. Neurochem Int. 2019;127:103\u201312.","journal-title":"Neurochem Int"},{"issue":"9","key":"760_CR44","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1016\/j.neurobiolaging.2009.10.009","volume":"32","author":"T Sato","year":"2011","unstructured":"Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, Iwamoto T. Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging. 2011;32(9):1626\u201333.","journal-title":"Neurobiol Aging"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-020-00760-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13195-020-00760-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-020-00760-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T10:35:40Z","timestamp":1697538940000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-020-00760-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,13]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["760"],"URL":"https:\/\/doi.org\/10.1186\/s13195-020-00760-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.09.17.302612","asserted-by":"object"}]},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,13]]},"assertion":[{"value":"17 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Cummings has provided consultation to Acadia, Actinogen, Alkahest, Alzheon, Annovis, Avanir, Axsome, Biogen, BioXcel, Cassava, Cerecin, Cerevel, Cortexyme, Cytox, EIP Pharma, Eisai, Foresight, GemVax, Genentech, Green Valley, Grifols, Karuna, Merck, Novo Nordisk, Otsuka, Resverlogix, Roche, Samumed, Samus, Signant Health, Suven, Third Rock, and United Neuroscience pharmaceutical and assessment companies. Dr. Cummings has stock options in ADAMAS, AnnovisBio, MedAvante, and BiOasis. Dr. Leverenz has received consulting fees from Acadia, Biogen, Eisai, GE Healthcare, and Sunovion.\u00a0The other authors have declared no competing interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24"}}